Title |
Lipid‐lowering agents for nephrotic syndrome
|
---|---|
Published in |
Cochrane database of systematic reviews, December 2013
|
DOI | 10.1002/14651858.cd005425.pub2 |
Pubmed ID | |
Authors |
Xiangyu Kong, Hao Yuan, Junming Fan, Zi Li, Taixiang Wu, Lanhui Jiang |
Abstract |
Nephrotic syndrome is the collective name given to a group of symptoms that include proteinuria, lipiduria, hypoalbuminaemia, oedema, hypercholesterolaemia, elevated triglycerides, and hyperlipidaemia. Hyperlipidaemia is thought to aggravate glomerulosclerosis (hardening of blood vessels in the kidneys) and enhance progression of glomerular disease. Studies have established that reduction in total cholesterol and low density lipoprotein (LDL) cholesterol is associated with reduction in risk of cardiovascular diseases. In 2011, the European Society of Cardiology and European Atherosclerosis Society guidelines for the management of dyslipidaemia recommended use of statins as first-line agents in the management of nephrotic dyslipidaemia. However, the effectiveness and safety of statins for people with nephrotic syndrome remains uncertain. Furthermore, the efficacy of second-line lipid-lowering drugs, such as ezetimibe and nicotinic acid, has not been proven in patients with nephrotic syndrome who are unable to tolerate statin therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 22% |
Mexico | 2 | 22% |
Ecuador | 1 | 11% |
Australia | 1 | 11% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 78% |
Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Scientists | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | <1% |
Netherlands | 1 | <1% |
Ireland | 1 | <1% |
Italy | 1 | <1% |
Unknown | 234 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 36 | 15% |
Student > Ph. D. Student | 27 | 11% |
Student > Master | 23 | 10% |
Researcher | 22 | 9% |
Student > Postgraduate | 18 | 8% |
Other | 49 | 21% |
Unknown | 63 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 90 | 38% |
Nursing and Health Professions | 27 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 4% |
Unspecified | 8 | 3% |
Biochemistry, Genetics and Molecular Biology | 6 | 3% |
Other | 24 | 10% |
Unknown | 73 | 31% |